The effect of L-dopa on the concentrations of tryptophan, tyrosine and serotonin in rat brain.

No abstract is available for this paper.

• Publication year

  1971

• Venue

  European Journal of Pharmacology

• Publication date

  1971-05-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/0014-2999(71)90195-6PMID 5157767
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effect of L-Dopa on monoamine metabolites in Parkinson's disease

  2005cited by this paper
• [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].

  1998cited by this paper
• L-Dopa: Effect on Concentrations of Dopamine, Norepinephrine, and Serotonin in Brains of Mice

  1970cited by this paper
• Accumulation of dopamine by blood platelets from normal subjects and parkinsonian patients under treatment with l‐DOPA

  1970cited by this paper
• A method for the simultaneous determination of 5-hydroxy-3-indole-acetic acid (5-HIAA) and 5-hydroxytryptamine (5-HT) in brain tissue and cerebrospinal fluid.

  1970cited by this paper
• Enhancement of tyrosine transamination in vivo by catecholamines

  1970cited by this paper
• L-Dopa-Induced Release of Cerebral Monoamines

  1970cited by this paper
• Psychosis and other psychiatric manifestations of levodopa therapy.

  1970cited by this paper
• L-Dopa: Effect of Concentrations of Dopamine, Norepinephrine, and Serotonin in Brains of Mice

  1970cited by this paper
• Further studies on tryptophan hydroxylase in rat brainstem and beef pineal.

  1969cited by this paper
• In vivo measurement of 5-hydroxytryptamine turnover rate in the rat brain from the conversion of C14-tryptophan to C14-5-hydroxytryptamine.

  1969cited by this paper
• Tryptophan Pyrrolase—A Biochemical Factor in Depressive Illness?

  1969cited by this paper
• Indolealkylamines and behavior.

  1968cited by this paper
• Indolealkylamines and behavior.

  1968cited by this paper
• 5-hydroxyindoleacetic and homovanillic acid levels in the cerebrospinal fluid of healthy volunteers and patients with Parkinson's syndrome.

  1967cited by this paper
• A study of the transport of 5-hydroxytryptophan and 5-hydroxytryptamine (serotonin) into brain.

  1963cited by this paper
• [The L-dihydroxyphenylalanine (L-DOPA) effect in Parkinson's syndrome in man: On the pathogenesis and treatment of Parkinson akinesis].

  1962cited by this paper
• [Distribution of 5-hydroxytryptamine (serotonin) in the human brain and its behavior in patients with Parkinson's syndrome].

  1961cited by this paper
• On the distribution in brain of monoamines and of enzymes responsible for their formation

  1959cited by this paper
• A fluorometric method for the estimation of tyrosine in plasma and tissues.

  1957cited by this paper

• Comprehensive blood metabolomics profiling of Parkinson’s disease reveals coordinated alterations in xanthine metabolism

  2024cites this paper
• Simultaneous detection of levodopa and serotonin using poly (CR) functionalised-MWCNT amplified carbon paste electrodes: A voltammetric investigation with Fukui analysis

  2024cites this paper
• Pre-mating nitenpyram exposure in male mice leads to depression-like behavior in offspring by affecting tryptophan metabolism in gut microbiota.

  2023cites this paper
• Niacin Enhancement for Parkinson’s Disease: An Effectiveness Trial

  2021cites this paper
• Vitamin B3: niacin and transcriptome analysis in relation to the GPR109A receptor

  2019cites this paper
• Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1).

  2018cites this paper
• Parkinson’s disease managing reversible neurodegeneration

  2016cites this paper
• Parkinson’s disease managing reversible neurodegeneration

  2016cites this paper
• Emerging preclinical pharmacological targets for Parkinson's disease

  2016cites this paper
• Parkinson’s disease managing reversible neurodegeneration

  2016cites this paper
• Synthesis, characterization and electrochemical properties of Co3O4 nanostructures by using cobalt hydroxide as a precursor

  2015cites this paper
• A novel treatment target for Parkinson's disease.

  2014cites this paper
• The Parkinson’s disease death rate: carbidopa and vitamin B6

  2014cites this paper
• Nanomolar simultaneous determination of levodopa and serotonin at a novel carbon ionic liquid electrode modified with Co(OH)2 nanoparticles and multi-walled carbon nanotubes

  2013cites this paper
• A novel electroanalytical method for simultaneous detection of two neurotransmitter dopamine and serotonin in human serum.

  2013cites this paper
• Mucuna pruriens seeds in treatment of Parkinson’s disease: pharmacological review

  2013cites this paper
• Neuropsychiatric Disease and Treatment 5-HTP efficacy and contraindications

  2012cites this paper
• 5-HTP efficacy and contraindications

  2012cites this paper
• A Selective Simultaneous Determination of Levodopa and Serotonin Using a Glassy Carbon Electrode Modified with Multiwalled Carbon Nanotube/Chitosan Composite

  2011cites this paper
• Amino acid management of Parkinson’s disease: a case study

  2011cites this paper
• A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole

  2010cites this paper
• Biologisch‐psychiatrischer Ansatz zur Therapie von Potenzstörungen *

  2009cites this paper
• Monoamine Oxidase Inhibitors and Serotonin Syndrome

  2007cites this paper
• A Precursor Study of the Indoleamine and Catecholamine Hypotheses of Depression Using the Dietary Tryptophan and Tyrosine Ratios

  2007cites this paper
• EEG sleep patterns in Parkinsonian patients treated with Bromocryptine and L-Dopa: A comparative study

  2005cites this paper
• n-3 fatty acids from fish and coronary artery disease: implications for public health

  2000cites this paper
• L-DOPA and quipazine elicit air-stepping in neonatal rats with spinal cord transections.

  1997cites this paper
• Effects of L-DOPA/carbidopa administration on the levels of L-DOPA, other amino acids and related compounds in the plasma, brain and heart of the rat.

  1997cites this paper
• Freezing of gait in Parkinson's disease is improved by treatment with weak electromagnetic fields.

  1996cites this paper
• [L-tyrosine: a long term treatment of Parkinson's disease].

  1989cites this paper
• L-Tryptophan: A Rational Anti-Depressant and a Natural Hypnotic?

  1988cites this paper
• Serotonin in involuntary movement disorders.

  1988cites this paper
• L-dopa induced "serotonin syndrome" in a parkinsonian patient on bromocriptine.

  1986cites this paper
• Control of Monoamine Synthesis by Precursor Availability

  1985cites this paper
• Treatment of depression by altering monoamine metabolism: precursors and metabolic inhibitors.

  1984cites this paper
• Treatment of Parkinson’s disease with agents other than Levodopa and Dopamine Agonists: controversies and new approaches

  1984cites this paper
• Tyrosine for the Treatment of Depression

  1984cites this paper
• Hypersexuality - a Complication of Dopaminergic Therapy in Parkinson's Disease

  1983cites this paper
• Tyrosine for depression.

  1982cites this paper
• [Effect of L-DOPA on brain serotonin metabolism related to tryptophan concentrations in plasma and brain of rats].

  1981cites this paper
• Open trial with levodopa‐carbidopa combination to patients with long‐standing progressive myoclonus epilepsy

  1981cites this paper
• Kinetics of L-DOPA metabolism in the caudate nucleus of cats with ventrotegmental lesions.

  1980cites this paper
• Noradrenalin, serotonin, and the dorsal horn.

  1980cites this paper
• Pain and tryptophan.

  1980cites this paper
• Quenching effects of various compounds on fluorometric assay of tryptophan.

  1979cites this paper
• The effects of p-chlorophenylalanine, reserpine, methysergide and cyproheptadine on the dopa-induced EEG synchronization in the rat.

  1978cites this paper
• Myoclonic attacks induced by L-Dopa and Bromocryptin in Parkinson patients

  1978cites this paper
• EEG sleep study in parkinsonian patients under bromocryptine treatment.

  1978cites this paper
• Pharmacological Agents as Tools in Psychiatric Research

  1977cites this paper
• Tryptophan in the central nervous system: Regulation and Significance

  1977cites this paper
• L-tryptophan administration in L-dopa-induced hallucinations in elderly Parkinsonian patients.

  1977cites this paper
• The effect of 5,6-dihydroxytryptamine on post-decapitation convulsions.

  1977cites this paper
• Studies on the mechanisms of L-dopa-induced depletion of 5-hydroxytryptamine in the mouse brain.

  1977cites this paper
• Tryptophan transport in brain synaptosomes: effects of L-DOPA.

  1976cites this paper
• Characterization of transport systems for the transfer of 3,4-L-dihydroxyphenylalanine into slices of rat cerebral cortex.

  1975cites this paper
• THE ACTIONS OF DIHYDROXYPHENYLALANINE AND DIHYDROXYPHENYLSERINE ON THE SLEEP‐WAKEFULNESS CYCLE OF THE RAT AFTER PERIPHERAL DECARBOXYLASE INHIBITION

  1975cites this paper
• Normalization of brain serotonin by L‐tryptophan in levodopa‐treated rats

  1975cites this paper
• Levodopa-induced myoclonus.

  1975cites this paper
• The Role of Catecholamines in Animal Learning and Memory

  1975cites this paper
• Mouse brain catecholamines, 5-hydroxytryptamine and the antinociceptive activity of pethidine.

  1975cites this paper
• Clinical studies with dopamine-receptor stimulants

  1975cites this paper
• The effect of L-dopa on exploratory activity after catecholamine receptors blocking agents.

  1974cites this paper
• Effects of L-dopa administration on the serotonergic system in rat brain: correlation between levels of L-dopa accumulated in the brain and depletion of serotonin and tryptophan.

  1974cites this paper
• Effects of exogenous monoamines and their precursors on the monoamine neurons of the central nervous system in rat.

  1974cites this paper
• Influence of quipazine, a potential anti-parkinsonian agent on the uptake of 3H-dopamine and 3H-serotonin into rat striatal tissue in vitro

  1973cites this paper
• The influence of L-DOPA perfusion concentrations and peripheral decarboxylase inhibition on dopa accumulation and decarboxylation in isolated perfused rat brains.

  1973cites this paper
• TRANSAMINATIONS BETWEEN AMINO ACIDS AND KETO ACIDS ELEVATED IN PHENYLKETONURIA AND MAPLE SYRUP URINE DISEASE

  1973cites this paper
• DOPA and amino acid levels in plasma and cerebrospinal fluid of patients with Parkinson's disease before and during treatment with L-DOPA.

  1973cites this paper
• Evidence for participation of a catecholaminergic mechanism in the post-castration rise in plasma gonadotropins.

  1973cites this paper
• The effect of lithium carbonate on the sleep of depressed patients.

  1973cites this paper
• [Effect of large doses of L-DOPA on the cerebral electrical activity of rabbits (interaction with the metabolism of 5-HT)].

  1973cites this paper
• Involvement of catecholamines in feedback mechanisms.

  1973cites this paper
• Effects of L-DOPA on the EEG and brain amines of unrestrained rats.

  1972cites this paper
• Effects of L-DOPA and L-3-O-methyl-DOPA on uptake of (3H)L-methionine by synaptosomes.

  1972cites this paper
• Clinical effects of para-chlorophenylalanine in Parkinson's disease.

  1972cites this paper
• L-Dopa and imipramine: biochemical and behavioral interaction.

  1972cites this paper
• Involvement of norepinephrine in transmission of the stimulatory influence of progesterone on gonadotropin release.

  1972cites this paper
• Antagonism of tremorine-induced tremor by serotoninergic agents in mice. Interactions with levodopa.

  1972cites this paper
• l‐Dihydroxyphenylalanine: Effect on levels of amino acids in rat brain 1

  1972cites this paper
• Effect of 5-hydroxydopamine on uptake and content of serotonin in rat striatum

  1972cites this paper
• Serotonin synthesis with rat brain synaptosomes. Effects of L-dopa, L-3-methoxytyrosine and catecholamines.

  1972cites this paper
• Clinical Pharmacology

  year unknowncites this paper
• Clinical Pharmacology

  year unknowncites this paper